PLoS ONE 2011-01-01

C1 Domain-targeted isophthalate derivatives induce cell elongation and cell cycle arrest in HeLa cells.

Virpi Talman, Raimo K Tuominen, Gustav Boije af Gennäs, Gustav Boije Af Gennäs, Jari Yli-Kauhaluoma, Elina Ekokoski

Index: PLoS ONE 6 , e20053, (2011)

Full Text: HTML

Abstract

Diacylglycerol (DAG)-mediated signaling pathways, such as those mediated by protein kinase C (PKC), are central in regulating cell proliferation and apoptosis. DAG-responsive C1 domains are therefore considered attractive drug targets. Our group has designed a novel class of compounds targeted to the DAG binding site within the C1 domain of PKC. We have previously shown that these 5-(hydroxymethyl)isophthalates modulate PKC activation in living cells. In this study we investigated their effects on HeLa human cervical cancer cell viability and proliferation by using standard cytotoxicity tests and an automated imaging platform with machine vision technology. Cellular effects and their mechanisms were further characterized with the most potent compound, HMI-1a3. Isophthalate derivatives with high affinity to the PKC C1 domain exhibited antiproliferative and non-necrotic cytotoxic effects on HeLa cells. The anti-proliferative effect was irreversible and accompanied by cell elongation. HMI-1a3 induced down-regulation of retinoblastoma protein and cyclins A, B1, D1, and E. Effects of isophthalates on cell morphology, cell proliferation and expression of cell cycle-related proteins were different from those induced by phorbol 12-myristate-13-acetate (PMA) or bryostatin 1, but correlated closely to binding affinities. Therefore, the results strongly indicate that the effect is C1 domain-mediated.


Related Compounds

Related Articles:

Bryostatin-1 promotes long-term potentiation via activation of PKCα and PKCε in the hippocampus.

2012-12-13

[Neuroscience 226 , 348-55, (2012)]

Bryostatin-I: A dendritic cell stimulator for chemokines induction and a promising adjuvant for a peptide based cancer vaccine

2010-01-01

[Cytokine 52(3) , 238-44, (2010)]

Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF.

2011-01-01

[Leuk. Res. 35(1) , 87-94, (2011)]

Enhancement of HLA class II-restricted CD4+ T cell recognition of human melanoma cells following treatment with bryostatin-1.

2011-01-01

[Cell. Immunol. 271(2) , 392-400, (2011)]

HLA class II defects in Burkitt lymphoma: bryostatin-1-induced 17 kDa protein restores CD4+ T-cell recognition.

2011-01-01

[Clin. Dev. Immunol. 2011 , 780839, (2011)]

More Articles...